Dr. Pallavi Kumar, M.D. - Baltimore, MD ...

Dr. Pallavi Kumar, MD

Claim this profile

Sinai Hospital of Baltimore

Studies Uterine Cancer
Studies Ovarian Cancer
11 reported clinical trials
44 drugs studied

Area of expertise

1

Uterine Cancer

Pallavi Kumar, MD has run 4 trials for Uterine Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage I
2

Ovarian Cancer

Pallavi Kumar, MD has run 3 trials for Ovarian Cancer.

Affiliated Hospitals

Image of trial facility.

Sinai Hospital Of Baltimore

Image of trial facility.

William E Kahlert Regional Cancer Center/Sinai Hospital

Clinical Trials Pallavi Kumar, MD is currently running

Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

More about Pallavi Kumar, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Pallavi Kumar, MD has experience with

  • Paclitaxel
  • Carboplatin
  • Pembrolizumab
  • Trastuzumab
  • Pertuzumab
  • RenovoCath

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Pallavi Kumar, MD specialize in?

Is Pallavi Kumar, MD currently recruiting for clinical trials?

Are there any treatments that Pallavi Kumar, MD has studied deeply?

What is the best way to schedule an appointment with Pallavi Kumar, MD?

What is the office address of Pallavi Kumar, MD?

Is there any support for travel costs?